Nataly Mirlas Neisberg

Nataly Mirlas Neisberg is currently working as a Research Team Leader at 1E Therapeutics since November 2021. Prior to this, Nataly was a CLD Scientist at Teva Pharmaceuticals from October 2018 to November 2021. Nataly began their career as a PHD Student at the Weizmann Institute of Science from December 2012 to October 2018, focusing on the molecular basis of DNA damage tolerance in mammalian cells. Earlier, Nataly worked as a Research Assistant at CrystalClear Ltd, concentrating on protein characterization and optimization of protein crystallization protocols. Nataly holds a Bachelor of Science degree in Biotechnology from Bar-Ilan University and a Master of Science degree in Neuroimmunology from the Weizmann Institute of Science.